Skip to main content
Premium Trial:

Request an Annual Quote

Oliver Fetzer, J. Craig Venter

Synthetic Genomics has appointed Oliver Fetzer as the company's new CEO, succeeding Co-founder J. Craig Venter, who will remain actively involved in SGI as executive chairman and co-chief scientist. Fetzer, who most recently served as president and CEO of Cerulean Pharma, will also be a member of SGI's board of directors. He also previously held management positions at Cubist Pharmaceuticals including senior VP of corporate development and R&D; senior VP of corporate development and chief business officer; and senior VP of business development.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.